iRadimed (NASDAQ:IRMD) Issues FY 2026 Earnings Guidance

iRadimed (NASDAQ:IRMD) updated its FY 2026 earnings guidance on Friday. The company provided EPS guidance of 2.060-2.210 for the period, compared to the consensus EPS estimate of 2.050. The company issued revenue guidance of $91.0 million-$96.0 million, compared to the consensus revenue estimate of $92.4 million. iRadimed also updated its Q2 2026 guidance to 0.440-0.480 EPS.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Freedom Capital raised shares of iRadimed to a “strong-buy” rating in a report on Thursday, April 2nd. Roth Mkm reaffirmed a “buy” rating and set a $120.00 price objective on shares of iRadimed in a report on Tuesday, February 10th. Finally, Lake Street Capital reaffirmed a “buy” rating and set a $120.00 price objective on shares of iRadimed in a report on Wednesday, February 11th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $120.00.

iRadimed Stock Down 0.3%

NASDAQ IRMD opened at $83.44 on Friday. The company has a market cap of $1.07 billion, a PE ratio of 47.68 and a beta of 1.11. iRadimed has a 52 week low of $50.31 and a 52 week high of $107.90. The firm’s 50-day simple moving average is $96.69 and its two-hundred day simple moving average is $93.87.

iRadimed (NASDAQ:IRMD) last announced its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.49 by $0.05. iRadimed had a return on equity of 23.83% and a net margin of 26.82%.The firm had revenue of $22.69 million for the quarter, compared to analysts’ expectations of $21.60 million. iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. As a group, equities research analysts anticipate that iRadimed will post 1.94 EPS for the current year.

iRadimed Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, March 6th. Stockholders of record on Monday, February 23rd were given a dividend of $0.20 per share. This is a boost from iRadimed’s previous quarterly dividend of $0.17. This represents a $0.80 annualized dividend and a dividend yield of 1.0%. The ex-dividend date was Monday, February 23rd. iRadimed’s dividend payout ratio (DPR) is currently 45.71%.

Insider Buying and Selling at iRadimed

In other news, CEO Roger E. Susi sold 3,750 shares of the company’s stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $89.16, for a total transaction of $334,350.00. Following the sale, the chief executive officer directly owned 2,198,750 shares in the company, valued at $196,040,550. This represents a 0.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 48,750 shares of company stock worth $4,708,950 in the last quarter. Corporate insiders own 36.80% of the company’s stock.

Institutional Investors Weigh In On iRadimed

Several hedge funds and other institutional investors have recently modified their holdings of IRMD. Royal Bank of Canada increased its position in shares of iRadimed by 14.7% during the first quarter. Royal Bank of Canada now owns 25,782 shares of the medical equipment provider’s stock valued at $1,354,000 after buying an additional 3,307 shares during the period. AQR Capital Management LLC increased its position in shares of iRadimed by 7.5% during the first quarter. AQR Capital Management LLC now owns 15,829 shares of the medical equipment provider’s stock valued at $831,000 after buying an additional 1,108 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of iRadimed by 5.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,811 shares of the medical equipment provider’s stock valued at $252,000 after buying an additional 234 shares during the period. Jones Financial Companies Lllp increased its position in shares of iRadimed by 8,568.5% during the first quarter. Jones Financial Companies Lllp now owns 11,269 shares of the medical equipment provider’s stock valued at $591,000 after buying an additional 11,139 shares during the period. Finally, Goldman Sachs Group Inc. increased its position in shares of iRadimed by 1.1% in the first quarter. Goldman Sachs Group Inc. now owns 169,387 shares of the medical equipment provider’s stock worth $8,889,000 after purchasing an additional 1,821 shares during the last quarter. 92.34% of the stock is currently owned by institutional investors.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.